Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Krisstina Gowin: The Blood Tells a Story Long Before Diagnosis – Are We Listening Early Enough?
Krisstina Gowin/LinkedIn
Apr 30, 2026, 16:51

Krisstina Gowin: The Blood Tells a Story Long Before Diagnosis – Are We Listening Early Enough?

Krisstina Gowin, Clinical Associate Professor at City of Hope, shared a post on LinkedIn about a recent article by Abhishek A Mangaonkar et al, published in American Jounal of Hematology, adding:

“The blood tells a story long before diagnosis. Are we listening early enough?

CHIP and CCUS represent one of the most compelling – and underutilized – frontiers in hematology, preventive oncology, and cardiovascular medicine.

A 2026 update in the American Journal of Hematology reinforces both the science and the urgency:

  • CHIP affects nearly 10% by age 70
  • VAF more than 10% – 11 times increased risk of hematologic malignancy
  • High-risk CCUS – up to 37% 2-year progression
  • Strong associations with atherosclerosis, stroke, heart failure, and metabolic disease

This is not a niche hematology issue – it is a systems biology challenge.

Pillar 1: Precursor Clinics

We need dedicated CH/CCUS clinics – now.

Structured programs allow for:

  • Risk-stratified surveillance
  • Germline evaluation
  • Cardio-oncology co-management
  • Early access to clinical trials – before transformation

The precursor state is the opportunity. We should be building infrastructure around it.

Pillar 2: Translational and Collaborative Science

We have risk tools – but they remain incomplete.

What we need:

  • Prospective natural history studies
  • Shared biobanks and datasets
  • AI-driven risk prediction beyond mutation plus VAF
  • Mechanistic insight into clonal expansion

Six interventional trials are already underway. This is momentum worth accelerating.

Pillar 3: Lifestyle as Intervention

Perhaps the most actionable – and underappreciated – lever.

Smoking, dyslipidemia, hypertension, metabolic health – these are not peripheral.

They shape clonal fitness and disease trajectory.

We are already counseling patients. Now we need the trials to prove impact.

Bottom line

CHIP and CCUS are not incidental findings.

They are biological signals – and a window of opportunity.

The field now needs:

  • Precursor clinics
  • Collaborative science
  • Intervention trials

The science is converging.

The time to act is now.”

Title: Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenias of Undetermined Significance: 2026 Update on Clinical Associations and Management Recommendations

Authors: Abhishek A Mangaonkar, Kelly L Bolton, Mrinal M Patnaik

Krisstina Gowin

Stay updated on all scientific advances with Hemostasis Today.

 

Abhishek A Mangaonkar American Jounal of Hematology CCUS CHIP Health Hematology Hemostasis Hemostasis News Hemostasis Today Kelly L. Bolton Krisstina Gowin Medicine Mrinal M. Patnaik
NewsFeed